Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies

References

• Roderburg C, Loosen SH, Kunstein A, Mohr R, Jördens MS, Luedde M, Kostev K, Luedde T. Cancer patients have an increased incidence of dementia: a retrospective cohort study of 185,736 outpatients in Germany. Cancers. 2021;13(9):2027.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590.
   PubMed Web of Science ®Google Scholar
• Mansour KA, Elbermawi A, Al-Karmalawy AA, Lahloub M-F, El-Neketi M. Cytotoxic effects of extracts obtained from plants of the Oleaceae family: bio-guided isolation and molecular docking of new secoiridoids from Jasminum humile. Pharm Biol. 2022;60(1):1374–1383.
   PubMed Web of Science ®Google Scholar
• Häder D-P, Williamson CE, Wängberg S-Å, Rautio M, Rose KC, Gao K, Helbling EW, Sinha RP, Worrest R. Effects of UV radiation on aquatic ecosystems and interactions with other environmental factors. Photochem Photobiol Sci. 2015;14(1):108–126.
   PubMed Web of Science ®Google Scholar
• Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer. 2012;107(7):1195–1202.
   PubMed Web of Science ®Google Scholar
• Attia EZ, Khalifa BA, Shaban GM, Amin MN, Akil L, Khadra I, Karmalawy AAA, Alnajjar R, Zaki MYW, Aly OM, et al. Potential topoisomerases inhibitors from Asergillus terreus using virtual screening. S Afr J Bot. 2022;149:632–645.
   Web of Science ®Google Scholar
• Al-Karmalawy AA, Nafie MS, Shaldam MA, Elmaaty AA, Antar SA, El-Hamaky AA, Saleh MA, Elkamhawy A, Tawfik HO. Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J Med Chem. 2023;66(1):777–792.
   PubMed Web of Science ®Google Scholar
• Dong H, Yin H, Zhao C, Cao J, Xu W, Zhang Y. Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors. Molecules. 2019;24(13):2407.
   PubMed Web of Science ®Google Scholar
• Hande KR. Topoisomerase II inhibitors. Updat Cancer Therapeut. 2008;3(1):13–26.
   Google Scholar
• Hammoud MM, Nageeb AS, Morsi MA, Gomaa EA, Elmaaty AA, Al-Karmalawy AA. Design, synthesis, biological evaluation, and SAR studies of novel cyclopentaquinoline derivatives as DNA intercalators, topoisomerase II inhibitors, and apoptotic inducers. New J Chem. 2022;46(23):11422–11436.
   Web of Science ®Google Scholar
• Villman K, Ståhl E, Liljegren G, Tidefelt U, Karlsson MG. Topoisomerase II- expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol. 2002;15(5):486–491.
   PubMed Web of Science ®Google Scholar
• Baldwin E, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005;5(4):363–372.
   PubMedGoogle Scholar
• Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem. 2022;37(1):299–314.
   PubMed Web of Science ®Google Scholar
• Romer DR. Synthesis of 2, 3‐dichloroquinoxalines via Vilsmeier reagent chlorination. J Heterocyclic Chem. 2009;46(2):317–319.
   Web of Science ®Google Scholar
• Ducray R, Ballard P, Barlaam BC, Hickinson MD, Kettle JG, Ogilvie DJ, Trigwell CB, Novel 3-alkoxy-1H-pyrazolo [3, D 4. ] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2008;18(3):959–962.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
   PubMed Web of Science ®Google Scholar
• Gallego J, Ortiz AR, de Pascual-Teresa B, Gago F. Structure–affinity relationships for the binding of actinomycin D to DNA. J Comput Aided Mol Des. 1997;11(2):114–128.
   PubMed Web of Science ®Google Scholar
• Bailey SA, Graves DE, Rill R. Binding of actinomycin D to the T (G) nT motif of double-stranded DNA: determination of the guanine requirement in nonclassical, non-GpC binding sites. Biochemistry. 1994;33(38):11493–11500.
   PubMed Web of Science ®Google Scholar
• Hamed MIA, Darwish KM, Soltane R, Chrouda A, Mostafa A, Abo Shama NM, Elhady SS, Abulkhair HS, Khodir AE, Elmaaty AA, et al. β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv. 2021;11(56):35536–35558.
   PubMed Web of Science ®Google Scholar
• Khattab M, Al-Karmalawy AA. Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med Chem. 2021;13(19):1623–1638.
   PubMed Web of Science ®Google Scholar
• Reed MD. The rescue and repurposing of pharmaceuticals: augmenting the drug development paradigm. Pediatric Pharmacy Advocacy Group. 2016;21:4–6.
   Google Scholar
• Elmaaty AA, Eldehna WM, Khattab M, Kutkat O, Alnajjar R, El-Taweel AN, Al-Rashood ST, Abourehab MAS, Binjubair FA, Saleh MA, et al. Anticoagulants as potential SARS-CoV-2 Mpro inhibitors for COVID-19 patients: in vitro, molecular docking, molecular dynamics, DFT, and SAR studies. IJMS. 2022;23(20):12235.
   Google Scholar
• Shazia P, Alnoman RB, Bayazeed AA, Alqahtani AM. Computational insights into the drug repurposing and synergism of FDA-approved influenza drugs binding with SARS-CoV-2 protease against COVID-19. Am J Microbiol Res. 2020;8(3):93–102.
   Google Scholar
• Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, Chrouda A, Pashameah RA, Mustafa M, Abu Mraheil M, et al. Coronavirus disease (COVID-19) control between drug repurposing and vaccination: A comprehensive overview. Vaccines. 2021;9(11):1317.
   Web of Science ®Google Scholar
• Abbas HA, Elsherbini AM, Shaldam MA. Repurposing metformin as a quorum sensing inhibitor in Pseudomonas aeruginosa. Afr H Sci. 2017;17(3):808–819.
   PubMed Web of Science ®Google Scholar
• Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat. 2020;52:100713.
   PubMed Web of Science ®Google Scholar
• Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, Man Y-g, Chen T. Antibiotics for cancer treatment: a double-edged sword. J Cancer. 2020;11(17):5135–5149.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers. 2019;11(8):1174.
   PubMed Web of Science ®Google Scholar
• Kingwell K. Antibiotics switch to anticancer target. Nat Rev Drug Discov. 2021;20(9):666.
   PubMed Web of Science ®Google Scholar
• Paul M, Gafter-Gvili A, Fraser A, Leibovici L. The anti-cancer effects of quinolone antibiotics? Eur J Clin Microbiol Infect Dis. 2007;26(11):825–831.
   PubMed Web of Science ®Google Scholar
• Qabaja A, Alshalalfa M, Alanazi E, Alhajj R. Prediction of novel drug indications using network driven biological data prioritization and integration. J Cheminform. 2014;6(1):1–14.
   PubMedGoogle Scholar
• Inc, C. Molecular operating environment (MOE). Chemical Computing Group Inc.; 2016. p. 1010. https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Inc%2C+C.+Molecular+operating+environment+%28MOE%29.+Chemical+Computing+Group+Inc.%3B&btnG=.
   Google Scholar
• Elshal M, Eid N, El-Sayed I, El-Sayed W, Al-Karmalawy AA. Concanavalin-A shows synergistic cytotoxicity with tamoxifen via inducing apoptosis in estrogen receptor-positive breast cancer: in vitro and molecular docking studies. Pharm Sci. 2021;28(1):76–85.
   Google Scholar
• Ma C, Taghour MS, Belal A, Mehany AB, Mostafa N, Nabeeh A, Eissa IH, Al-Karmalawy AA. Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies. Front Chem. 2021;9. https://doi.org/10.3389/fchem.2021.725135.
   Web of Science ®Google Scholar
• Taher RF, Al-Karmalawy AA, Abd El Maksoud AI, Khalil H, Hassan A, El-Khrisy E-DA, El-Kashak W. Two new flavonoids and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies. J Herbmed Pharmacol. 2021;10(4):443–458.
   Google Scholar
• Al-Karmalawy AA, Farid MM, Mostafa A, Ragheb AYH, Mahmoud S, Shehata M, Shama NMA, GabAllah M, Mostafa-Hedeab G, Marzouk MM. Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2. Molecules. 2021;26(21):6559.
   PubMed Web of Science ®Google Scholar
• Elebeedy D, Badawy I, Elmaaty AA, Saleh MM, Kandeil A, Ghanem A, Kutkat O, Alnajjar R, Abd El Maksoud AI, Al-Karmalawy AA. In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comput Biol Med. 2022;141:105149.
   PubMed Web of Science ®Google Scholar
• Elmaaty AA, Darwish KM, Chrouda A, Boseila AA, Tantawy MA, Elhady SS, Shaik AB, Mustafa M, Al-Karmalawy AA. In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega. 2022;7(1):875–899.
   PubMed Web of Science ®Google Scholar
• Zaki AA, Ashour A, Elhady SS, Darwish KM, Al-Karmalawy AA. Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: Molecular docking, molecular dynamics, and SAR studies. J Tradit Complement Med. 2022;12(1):16–34.
   PubMedGoogle Scholar
• Elmaaty AA, Darwish KM, Khattab M, Elhady SS, Salah M, Hamed MIA, Al‐Karmalawy AA, Saleh MM. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J Biomol Struct Dyn. 2022;40(19):1–28.
   Web of Science ®Google Scholar
• Tools M-DI. Schrödinger: New York (NY): Schrödinger; 2017.
   Google Scholar
• Elagawany M, Elmaaty AA, Mostafa A, Abo Shama NM, Santali EY, Elgendy B, Al-Karmalawy AA. Ligand-based design, synthesis, computational insights, and in vitro studies of novel N-(5-Nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease. J Enzyme Inhib Med Chem. 2022;37(1):2112–2132.
   PubMed Web of Science ®Google Scholar
• Betancur-Galvis LA, Morales G, Forero J, Roldan J. Cytotoxic and antiviral activities of Colombian medicinal plant extracts of the Euphorbia genus. Mem Inst Oswaldo Cruz. 2002;97(4):541–546.
   PubMed Web of Science ®Google Scholar
• Kutkat O, Moatasim Y, Al‐Karmalawy AA, Abulkhair HS, Gomaa MR, El-Taweel AN, Abo Shama NM, GabAllah M, Mahmoud DB, Kayali G, et al. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies. Sci Rep. 2022;12(1):12920.
   PubMed Web of Science ®Google Scholar
• Mahmoud A, Mostafa A, Al-Karmalawy AA, Zidan A, Abulkhair HS, Mahmoud SH, Shehata M, Elhefnawi MM, Ali MA. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon. 2021;7(9):e07962.
   PubMed Web of Science ®Google Scholar
• El-Azab MF, Al-Karmalawy AA, Antar SA, Hanna PA, Tawfik KM, Hazem RM. A novel role of Nano selenium and sildenafil on streptozotocin-induced diabetic nephropathy in rats by modulation of inflammatory, oxidative, and apoptotic pathways. Life Sci. 2022;303:120691.
   PubMed Web of Science ®Google Scholar
• El-Demerdash A, Al-Karmalawy AA, Abdel-Aziz TM, Elhady SS, Darwish KM, Hassan AHE. Investigating the structure–activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC Adv. 2021;11(50):31339–31363.
   PubMed Web of Science ®Google Scholar
• Elebeedy D, Elkhatib WF, Kandeil A, Ghanem A, Kutkat O, Alnajjar R, Saleh MA, Abd El Maksoud AI, Badawy I, Al-Karmalawy AA. Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Adv. 2021;11(47):29267–29286.
   PubMed Web of Science ®Google Scholar
• Elmaaty AA, Alnajjar R, Hamed MI, Khattab M, Khalifa MM, Al-Karmalawy AA. Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv. 2021;11(17):10027–10042.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Abou-El-Regal MM, El-Metwally SA, Sherbiny FF, Eissa IH. Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents. Mol Divers. 2017;21(4):967–983.
   PubMed Web of Science ®Google Scholar
• El-Masry RM, Al-Karmalawy AA, Alnajjar R, Mahmoud SH, Mostafa A, Kadry HH, Abou-Seri SM, Taher AT. Newly synthesized series of oxoindole–oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies. New J Chem. 2022;46(11):5078–5090.
   Web of Science ®Google Scholar
• El Gizawy HA, Boshra SA, Mostafa A, Mahmoud SH, Ismail MI, Alsfouk AA, Taher AT, Al-Karmalawy AA. Pimenta dioica (L.) Merr. bioactive constituents exert anti-SARS-CoV-2 and anti-inflammatory activities: molecular docking and dynamics, in vitro, and in vivo studies. Molecules. 2021;26(19):5844.
   PubMed Web of Science ®Google Scholar
• Alnajjar R, Mostafa A, Kandeil A, Al-Karmalawy AA. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon. 2020;6(12):e05641.
   PubMed Web of Science ®Google Scholar
• Oyama T, Maruyama I, Aikou T. Roxithromycin inhibits constitutive activation of nuclear factor KB by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res. 2005;11(15):5645–5650.
   Google Scholar
• Chlebda E, Merwid-L1d A, Szumny D, Trocha M. g, Fereniec-Go³Êbiewska L, Gebarowska E, Kowalski P, Szel1g A. Antitumor effect of macrolides–erythromycin and roxithromycin in B16 melanoma-transplanted mice. Pharmacol Rep. 2007;59:269–274.
   Web of Science ®Google Scholar
• Ozkan T, Hekmatshoar Y, Karabay AZ, Koc A, Altinok Gunes B, Karadag Gurel A, Sunguroglu A. Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. Leuk Res. 2021;102:106523.
   PubMed Web of Science ®Google Scholar
• Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, Yokogawa K, Miyamoto K-i, Hasegawa T. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol. 2000;27(8):587–593.
   PubMed Web of Science ®Google Scholar
• Ishimatsu Y, Mukae H, Sakamoto N. Activity of clarithromycin in mucosa-associated lymphoid tissue-type lymphomas: response. Chest. 2011;139(3):725–726.
   Web of Science ®Google Scholar
• Ferreri AJ. Activity of clarithromycin in mucosa-associated lymphoid tissue-type lymphomas: antiproliferative drug or simple antibiotic? Chest. 2011;139(3):724–725.
   PubMed Web of Science ®Google Scholar
• Ishii A, Kumasaka M, Nagashima Y, Nakajima Y, Kuramochi K, Sugawara F, Narukawa M, Kamakura T. A eukaryotic molecular target candidate of roxithromycin: fungal differentiation as a sensitive drug target analysis system. Biosci Biotechnol Biochem. 2013;77(7):1539–1547.
   PubMed Web of Science ®Google Scholar
• Teixeira DS, Louzeiro GC, Figueiredo M, Cherubini K, Salum FG. Erythromycin: an alternative for the management of oral mucositis? Medicina Oral, Patologia Oral y Cirugia Bucal. 2022;27(5):25439–25439.
   Web of Science ®Google Scholar